格隆汇6月27日丨健世科技-B(09877.HK)发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验(“TRINITY”)中大瓣环患者30天临床随访结果于美国举行的2025年纽约瓣膜会发布。
TRINITY是一项全球前瞻性、多中心、单臂临床试验，主要用于评估LuX-Valve Plus于重度三尖瓣反流及外科高危患者中应用的安全性及有效性。该项研究全分析集(FAS)共纳入全球20家中心的149例患者，其中18家中心分布在法国、德国、英国、西班牙、丹麦等欧洲国家。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.